Background: The impact of resistance to antimalarials is insidious and unless efficacy studies are conducted, resistance may go unrecognized. The aim of this study was to assess the efficacy of artemether/lumefantrine, for the treatment of uncomplicated Plasmodium falciparum infections in Kemisie Health Center, Northeast Ethiopia.Methods: Artemether/lumefantrine efficacy study was conducted in Kemisie Health Center, Northeast Ethiopia from September, 2012 to May, 2013. The study participants were febrile people above the age of 6 months with confirmed uncomplicated P. falciparum infection. Patients were treated with artemether/lumefantrine. Clinical and parasitological parameters were monitored over a 28 days follow-up period to evaluate dr...
Background: Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malar...
Background: Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malar...
Background: Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malar...
Background: Artemether-lumefantrine (AL) has been used as a first-line treatment for uncomplicated P...
Background: Artemether-lumefantrine (AL) has been used as a first-line treatment for uncomplicated P...
Background: Artemether-lumefantrine (AL) has been used as a first-line treatment for uncomplicated P...
Malaria is an important cause of death and illness in children and adults, especially in tropical co...
Background In vivo efficacy assessments of the first-line treatments for Plasmodium falciparum malar...
Background: In Jimma Zone, Ethiopia, the first-line treatment of uncomplicated falciparum malaria ha...
Background: In Jimma Zone, Ethiopia, the first-line treatment of uncomplicated falciparum malaria ha...
Background: In Jimma Zone, Ethiopia, the first-line treatment of uncomplicated falciparum malaria ha...
Background: In Jimma Zone, Ethiopia, the first-line treatment of uncomplicated falciparum malaria ha...
Abstract Background In vivo efficacy assessments of the first-line treatments for Plasmodium falcipa...
Purpose: Following the increased Plasmodium falciparum resistance to chloroquine and sulfadoxine/pyr...
Background: Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malar...
Background: Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malar...
Background: Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malar...
Background: Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malar...
Background: Artemether-lumefantrine (AL) has been used as a first-line treatment for uncomplicated P...
Background: Artemether-lumefantrine (AL) has been used as a first-line treatment for uncomplicated P...
Background: Artemether-lumefantrine (AL) has been used as a first-line treatment for uncomplicated P...
Malaria is an important cause of death and illness in children and adults, especially in tropical co...
Background In vivo efficacy assessments of the first-line treatments for Plasmodium falciparum malar...
Background: In Jimma Zone, Ethiopia, the first-line treatment of uncomplicated falciparum malaria ha...
Background: In Jimma Zone, Ethiopia, the first-line treatment of uncomplicated falciparum malaria ha...
Background: In Jimma Zone, Ethiopia, the first-line treatment of uncomplicated falciparum malaria ha...
Background: In Jimma Zone, Ethiopia, the first-line treatment of uncomplicated falciparum malaria ha...
Abstract Background In vivo efficacy assessments of the first-line treatments for Plasmodium falcipa...
Purpose: Following the increased Plasmodium falciparum resistance to chloroquine and sulfadoxine/pyr...
Background: Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malar...
Background: Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malar...
Background: Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malar...
Background: Tanzania adopted artemether-lumefantrine (AL) as first-line drug for uncomplicated malar...